May 4, 2017 at 11 am PT/2 pm ET
Webinar: 23andMe’s New FDA-Authorized Health Reports
Earlier this month, the FDA authorized 23andMe to provide genetic risk information for certain health conditions, including AATD, late-onset Alzheimer’s disease and more.
Studies show that many consumers want to know their genetic health risk even for conditions that have no current prevention or treatments,1 and that about 30% of people who get over-the-counter (OTC) genetic testing share their results with healthcare providers.2,3,4
As genetic health information becomes more accessible to consumers—23andMe has genotyped more than 2 million people—your patients are more likely to discuss genetic health risks with you.
Watch this 23andMe webinar to learn about the new Genetic Health Risk reports*, including the science behind our tests and how genetic risk information is communicated to consumers. The webinar features 23andMe’s Shirley Wu, PhD, Director of Product Science, and Stacey Detweiler, MS, LCGC, Genetic Counselor and Medical Affairs Associate.
This webinar is intended for healthcare professionals, though it is open to educators, researchers, students and lifelong learners.
View sample reports and package inserts for Genetic Health Risk reports.